Trevi Therapeutics, Inc. (TRVI) Financials

TRVI Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 330.5 million 9.0 million
March 31, 2026 179.6 million 7.5 million
Dec. 31, 2025 193.4 million 10.2 million
Sept. 30, 2025 199.4 million 9.6 million

TRVI Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -17.6 million 3.3 million
March 31, 2026 -16.8 million 2.2 million
Dec. 31, 2025 5.8 million 1.4 million
Sept. 30, 2025 -10.9 million 1.2 million

TRVI Net Income

No data available :(

TRVI Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 318.9 million - 605000
March 31, 2026 171.8 million 364000 318000
Dec. 31, 2025 188.3 million - 753000
Sept. 30, 2025 194.9 million - 823000

TRVI Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 156.6 million
March 31, 2026 145.6 million
Dec. 31, 2025 145.5 million
Sept. 30, 2025 145.1 million

TRVI Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 124000 15.2 million 5.4 million -
March 31, 2026 102000 9.9 million 5.0 million -
Dec. 31, 2025 13.5 million 6.2 million 4.0 million -
Sept. 30, 2025 12000 10.1 million 3.8 million -

TRVI Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 34000
Dec. 31, 2025 - 31000
Sept. 30, 2025 - -

TRVI

Price: $18.46

52 week price:
6.55
20.22

Earnings Per Share: -0.35 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 28000

Market Capitalization: 2.5 billion

Links: